FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2530671848> ?p ?o ?g. }

• W2530671848 endingPage "2551" @default.
• W2530671848 startingPage "2551" @default.
• W2530671848 abstract "2551 Background: A multimodal approach based on debulking surgery is beneficial in the treatment of pleural mesothelioma (PM). In addition, hyperthermic intra-thoracic chemotherapy significantly improves patient survival. Chemotherapeutic agents such as gemcitabin (Gem) have proven their efficacy in PM. The aim of this study was to assess the feasibility, tolerability and pharmacokinetics (PK) of gemcitabine (Gem)-cisplatine (Pt) both administered using this new intra-thoracic hyperthermic schedule. Methods: A phase II study was conducted in patients with T<3, N<2, M0 epithelioid mesothelioma. After neoadjuvant chemotherapy (Gem-Pt), extra-pleural pneumonectomy with diaphragmatic and pericardic reconstruction was performed, followed by a 1-hour intra-thoracic hyperthermic infusion of Pt (100 mg/m²) + Gem (1250 mg/m²). Pleural and blood samples were analyzed for Gem and its active metabolite difluorodeoxyuridine (dFdU, HPLC assay) and for total and free Pt concentrations (atomic absorption spectrophotometry). Five patients were analyzed for PK. Results: No major chemotherapy-related side effect was reported. Main PK data are the following: the maximum dFdU concentration was reached between 1.25 and 1.5 h in pleura, and between 1.25 and 4 h in plasma. For free Pt, maximum concentrations were observed between 0.25 and 1 h in pleura and between 1 and 1.25 h in plasma. Large inter-patient variability was observed for both dFdU and free Pt PK. Importantly, the local exposure to dFdU was 2.5 to 9-fold that of plasma exposure. For free Pt, pleural exposure was 8.7 to 30-fold greater than plasma exposure. Conclusions: These data indicate a markedly higher pleural exposure as compared to systemic exposure for dFdU and Pt. Along with satisfactory tolerance, these results support the potential benefit offered by this new intra-thoracic hyperthermic schedule in the management of PM. Patient AUC0–48h dFdU (μM.h) AUC0–48h free Pt (mg/l.h) Plasma Pleura Pleura/plasma Plasma Pleura Pleura/plasma 1 913 2,350 2.57 6.96 60.65 8.71 2 304 1,396 4.59 5.44 not done - 3 379 953 2.51 1.87 56.68 30.31 4 537 4,856 9.04 4.26 100.87 23.68 5 386 1,453 3.76 1.82 29.72 16.29 No significant financial relationships to disclose." @default.
• W2530671848 created "2016-10-21" @default.
• W2530671848 creator A5002597256 @default.
• W2530671848 creator A5006266119 @default.
• W2530671848 creator A5023825873 @default.
• W2530671848 creator A5029862075 @default.
• W2530671848 creator A5057185222 @default.
• W2530671848 creator A5066629935 @default.
• W2530671848 creator A5080447107 @default.
• W2530671848 creator A5087743050 @default.
• W2530671848 creator A5090050048 @default.
• W2530671848 date "2008-05-20" @default.
• W2530671848 modified "2023-10-18" @default.
• W2530671848 title "A novel intra-thoracic hyperthermic schedule combining gemcitabine (Gem) and cisplatin (Pt) in patients with pleural mesothelioma: A pharmacokinetic analysis" @default.
• W2530671848 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.2551" @default.
• W2530671848 hasPublicationYear "2008" @default.
• W2530671848 type Work @default.
• W2530671848 sameAs 2530671848 @default.
• W2530671848 citedByCount "0" @default.
• W2530671848 crossrefType "journal-article" @default.
• W2530671848 hasAuthorship W2530671848A5002597256 @default.
• W2530671848 hasAuthorship W2530671848A5006266119 @default.
• W2530671848 hasAuthorship W2530671848A5023825873 @default.
• W2530671848 hasAuthorship W2530671848A5029862075 @default.
• W2530671848 hasAuthorship W2530671848A5057185222 @default.
• W2530671848 hasAuthorship W2530671848A5066629935 @default.
• W2530671848 hasAuthorship W2530671848A5080447107 @default.
• W2530671848 hasAuthorship W2530671848A5087743050 @default.
• W2530671848 hasAuthorship W2530671848A5090050048 @default.
• W2530671848 hasConcept C112705442 @default.
• W2530671848 hasConcept C126322002 @default.
• W2530671848 hasConcept C126894567 @default.
• W2530671848 hasConcept C142724271 @default.
• W2530671848 hasConcept C2776694085 @default.
• W2530671848 hasConcept C2777407522 @default.
• W2530671848 hasConcept C2778239845 @default.
• W2530671848 hasConcept C2779949491 @default.
• W2530671848 hasConcept C2780258809 @default.
• W2530671848 hasConcept C71924100 @default.
• W2530671848 hasConceptScore W2530671848C112705442 @default.
• W2530671848 hasConceptScore W2530671848C126322002 @default.
• W2530671848 hasConceptScore W2530671848C126894567 @default.
• W2530671848 hasConceptScore W2530671848C142724271 @default.
• W2530671848 hasConceptScore W2530671848C2776694085 @default.
• W2530671848 hasConceptScore W2530671848C2777407522 @default.
• W2530671848 hasConceptScore W2530671848C2778239845 @default.
• W2530671848 hasConceptScore W2530671848C2779949491 @default.
• W2530671848 hasConceptScore W2530671848C2780258809 @default.
• W2530671848 hasConceptScore W2530671848C71924100 @default.
• W2530671848 hasIssue "15_suppl" @default.
• W2530671848 hasLocation W25306718481 @default.
• W2530671848 hasOpenAccess W2530671848 @default.
• W2530671848 hasPrimaryLocation W25306718481 @default.
• W2530671848 hasRelatedWork W2050291724 @default.
• W2530671848 hasRelatedWork W2100029565 @default.
• W2530671848 hasRelatedWork W2118212877 @default.
• W2530671848 hasRelatedWork W2142448385 @default.
• W2530671848 hasRelatedWork W2361287035 @default.
• W2530671848 hasRelatedWork W2371670911 @default.
• W2530671848 hasRelatedWork W2374795505 @default.
• W2530671848 hasRelatedWork W2381460883 @default.
• W2530671848 hasRelatedWork W2906520136 @default.
• W2530671848 hasRelatedWork W2977610808 @default.
• W2530671848 hasVolume "26" @default.
• W2530671848 isParatext "false" @default.
• W2530671848 isRetracted "false" @default.
• W2530671848 magId "2530671848" @default.
• W2530671848 workType "article" @default.